Advertisement

Inhibitors of lymphocyte activation secreted by human melanoma cell lines

  • Dario Giacomoni
  • Shlomo Ben-Efraim
  • Feridoon Najmabadi
  • Sheldon Dray
Article
  • 14 Downloads

Abstract

The concentrated supernatants of nine human melanoma cell line cultures were analyzed for the presence of factors that inhibitin vitro immunological reactions. All cell lines secreted a factor that inhibited LPS-induced proliferation of murine B cells; eight cell lines released a factor that inhibited PHA-induced proliferation of murine T cells; all of the three cell lines investigated secreted a factor that inhibited the allogeneic stimulation of BALB/c spleen cells by mitomycin-C-treated C57BL spleen cells. Further analysis of the M21 cell supernatant indicated that its continuous presence was required for the inhibition of the PHA but not of the LPS response suggesting a different mechanism of action. High levels of PHA, but not of LPS, could overcome the inhibitory effect of M21 supernatants. Fractionation of M21 supernatants by sucrose gradient centrifugation, DEAE chromatography and gel filtration suggested that the anti-PHA and the anti-LPS activities were due to different factors. These factors differed from a serine proteinase inhibitor that is also released by M21 cells. Since these inhibitory factors may have a role in protecting a melanoma tumor from attack by the immune system of the host, their consideration may be helpful in designing protocols for therapy which include methods to boost the antitumor responses of the host.

Key words

Human melanoma Immunological inhibitions Lymphocyte activation 

References

  1. 1.
    Nelson, D S, Nelson M: Evasion of host defenses by tumors.Immunol Cell Biol 65, 287–304 (1987).PubMedCrossRefGoogle Scholar
  2. 2.
    Roth J A, Osborne B A, Ames R S: Immunoregulatory factors derived from human tumors II. Partial purification and further immunobiochemical characterization of a human sarcoma-derived immunosup-pressive factor expressing HLA-OR and Immunoglobulin related determinant.J Immunol 130, 303–308 (1983).PubMedGoogle Scholar
  3. 3.
    Putnam J B, Roth J A: Identification and characterization of a tumor derived immunosuppressive gly-coprotein from murine melanoma K-1735.Cancer Immunol Immunother 19, 90–100 (1985).PubMedCrossRefGoogle Scholar
  4. 4.
    Hoagland J G, Scoggin S, Giavazzi R, Campbell D, Kanellopoulos K, Jessup J M: Tumor derived suppressor factors (TDSFs) in normal and neoplastic colon and rectum.Surg Res 40, 467–474 (1986).CrossRefGoogle Scholar
  5. 5.
    Cornelius J C, Normal S J: Isolation of a low M.W. inhibitor of lymphocyte proliferation from tumorous ascites.J Immunol 141, 2175–2180 (1988).PubMedGoogle Scholar
  6. 6.
    Whitehead J S, Kim Y S: An inhibitor of lymphocyte proliferation produced by a human colonic adenocar- cinoma cell line in culture.Cancer Res 40, 29–35 (1980).PubMedGoogle Scholar
  7. 7.
    Najmabadi F, Giacomoni D, Dray S: Serine pro-teinase inhibitors produced by human melanoma cell lines.Tumor Biol 11, 39–50 (1990).CrossRefGoogle Scholar
  8. 8.
    Muller-Eberhard H J: The membrane attack complex of complement.Ann Rev Immunol 4, 503–528 (1986).Google Scholar
  9. 9.
    Pasternack M S, Verret C R, Liu M H, Eisen H N: Serine esterases in cytolytic T lymphocytes.Nature 322, 740–743 (1986).PubMedCrossRefGoogle Scholar
  10. 10.
    Kaplan J C, Bona C: Proteases as mitogens.Exp Cell Res 88, 388–396 (1974).PubMedCrossRefGoogle Scholar
  11. 11.
    Bromke B J, Kueppers F: The major urinary protease inhibitor: Simplified purification and characterization.Biochem Med 27, 56–67 (1982).PubMedCrossRefGoogle Scholar
  12. 12.
    Werkmeister J, Zbroja R, McCarthy W, Hersey P: Detection of an inhibitor of cell division in cultures of tumor cells with immunosuppressive activityin vitro.Clin exp Immunol 40, 168–177 (1980).PubMedGoogle Scholar
  13. 13.
    Cordiali-Fei P, Mottolese M, Tecce R, Natali P, Ferrone S: Accessory cell function of human melanoma cells in mitogen-induced T-cell proliferation.Cell Immunol 116, 149–162 (1988).PubMedCrossRefGoogle Scholar
  14. 14.
    Ye Q W, Mokyr M B, Pyle J M, Dray S: Suppression of antitumor immunity by macrophages bearing a large MOPC-315 tumor.Cancer Immunol Immunother 16, 162–169 (1984).PubMedCrossRefGoogle Scholar
  15. 15.
    Nahas F, Ophir R, Ben-Efraim S: Effect of melphalan administration on the activity of natural killer and natural cytotoxic spleen cells of normal and tumor-bearing mice.Immunology Lett 10, 333–337 (1985).CrossRefGoogle Scholar
  16. 16.
    Shoval S, Ophir R, Ben-Efraim S: Deficiency in immunocompetence of mice cured from large MOPC- 315 plasmacytoma by melphalan therapy.Cancer Immunol Immunother 29, 279–287 (1989).PubMedCrossRefGoogle Scholar
  17. 17.
    Wise J A, Mokyr M B, Dray S: Effect of low dose cyclophosphamide therapy on specific and nonspecific T cell-dependent responses of spleen cells from mice bearing large MOPC-315 plasmacytomas.Cancer Immunol Immunother 27, 191–197 (1988).PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 1990

Authors and Affiliations

  • Dario Giacomoni
    • 1
  • Shlomo Ben-Efraim
    • 1
  • Feridoon Najmabadi
    • 1
  • Sheldon Dray
    • 1
  1. 1.Department of Microbiology and ImmunologyUniversity of Illinois at ChicagoChicagoUSA

Personalised recommendations